

R⁶, at each occurrence, is independently selected from: halogen, C₁₋₄ alkyl, and C₁₋₄ alkoxy.

10. A compound according to claim 1, wherein the compound is selected from the exemplified examples or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 10, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

12. The use of the pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical composition further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, ~~treatments for heart failure, treatments for peripheral arterial disease and~~ anti-inflammatory agents.

13. The pharmaceutical composition according to claim 11, further comprising a dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.

14. The use of a compound of any one of claims 1 to 10 in the manufacture of a medicament for the ~~for use in prevention~~ preventing, modulation ~~modulating or treatment~~ of ~~treatment~~ diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, acute coronary syndrome, delayed wound healing,